Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) is a commercial-stage rare disease company whose news flow centers on its therapies for serious, low-prevalence conditions and the corporate developments that support these programs. The company regularly issues updates describing progress with its approved products, clinical pipeline, regulatory interactions, and financial performance.
A major theme in Zevra’s news is the commercialization and clinical evidence for MIPLYFFA (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC). Press releases highlight pivotal and long-term data, presentations at scientific and patient-focused meetings, and steps to broaden access, such as a distribution agreement with Uniphar to enable reimbursed named patient supply for NPC patients in select territories outside Europe. These items provide insight into how Zevra is working to expand the reach of its NPC treatment.
News coverage also includes updates on OLPRUVA (sodium phenylbutyrate), Zevra’s approved treatment for certain urea cycle disorders, and on celiprolol, its investigational candidate for vascular Ehlers-Danlos syndrome. The company reports on clinical trial enrollment milestones, publication of new analyses, and recognition of its scientific work at conferences, giving investors and clinicians visibility into the evolution of its rare disease portfolio.
In addition, Zevra issues quarterly financial results and corporate updates, detailing revenue contributions from its commercial products, operating expenses, and capital resources. Governance and organizational news, such as board appointments, executive transitions, and equity inducement grants under its employment inducement award plan, are disclosed through press releases and Form 8-K filings. For anyone tracking ZVRA, this news stream offers a consolidated view of the company’s therapeutic progress, regulatory status, and corporate trajectory in the rare disease space.
Zevra Therapeutics (NASDAQ: ZVRA) said its executive leadership will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 15, 2026 at 9:45 a.m. PT. Management will also hold one-on-one meetings with registered attendees. A live webcast will be available via the company’s Investor Relations "Events & Presentations" page at investors.zevra.com.
Zevra Therapeutics (Nasdaq: ZVRA) executed an exclusive expanded access distribution agreement with Uniphar to broaden patient access to MIPLYFFA (arimoclomol) for reimbursed named-patient supply in select territories outside Europe. MIPLYFFA is FDA-approved and commercially available in the U.S.; a Marketing Authorisation Application for NPC has been validated and is under review by the European Medicines Agency. Zevra said the deal leverages Uniphar’s global distribution capabilities while the company continues U.S. commercialization and prepares for potential EU approval.
Zevra Therapeutics (Nasdaq: ZVRA) announced on Dec 12, 2025 that it granted options to purchase an aggregate of 53,000 shares of common stock as inducement awards to three new employees under its 2023 Employment Inducement Award Plan. Each award vests over four years with 25% vesting on the first anniversary of employment and the remainder in three equal annual installments, subject to continued employment.
Each award was granted as an inducement material to the individual entering employment in accordance with Nasdaq Rule 5635(c)(4). The Inducement Award Plan is reserved for individuals not previously employed or returning after a bona fide non-employment period.
Zevra Therapeutics (NasdaqGS: ZVRA) announced on December 2, 2025 the appointment of Alicia Secor to its Board of Directors and the retirement of director Wendy Dixon, PhD, effective the same date. The company said Secor brings more than 30 years of life sciences experience, including recent roles as President and CEO of Atalanta Therapeutics and prior CEO of Juniper Pharmaceuticals (acquired by Catalent in 2018), plus senior leadership at Genzyme and board roles at multiple biotech firms. Zevra’s chair and CEO each commented that Secor’s rare‑disease expertise will support strategy execution and thanked Dixon for her service.
Zevra Therapeutics (NasdaqGS: ZVRA) announced that Chief Financial Officer and Treasurer R. LaDuane Clifton will step down effective December 31, 2025 to pursue other professional opportunities. Clifton has served since 2015, and company leadership said he helped guide Zevra from development stage to a commercial-stage rare disease company and left a strong financial foundation.
The company has initiated a search for a new chief financial officer. No replacement has been named and no financial metrics or guidance changes were disclosed.
Zevra Therapeutics (Nasdaq: ZVRA) reported Q3 2025 results: net revenue $26.1M driven by MIPLYFFA $22.4M, compared with $3.7M in Q3 2024. Q3 net loss was $0.5M (−$0.01 per share) versus a $33.2M loss a year earlier. Cash, cash equivalents and securities were $230.4M as of September 30, 2025, supporting the company’s operating plan. Clinical and regulatory progress includes an EMA-validated MAA for arimoclomol (orphan designation) and ongoing Phase 3 DiSCOVER enrollment for celiprolol (44 patients enrolled). The company reduced OLPRUVA commercial effort while maintaining product availability.
Zevra Therapeutics (NasdaqGS: ZVRA) said members of its executive leadership will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on Wednesday, November 12, 2025 at 11:30 a.m. ET.
Management will also hold one-on-one meetings with registered attendees. A live webcast will be available via the company’s Investor Relations Events & Presentations page at investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA) will report Q3 2025 corporate and financial results on Wednesday, November 5, 2025 after market close. The company will host a conference call and audio webcast the same day at 4:30 p.m. ET.
A webcast link and replay (available for 90 days) are accessible on the Events & Presentations page in the Investor Relations section at investors.zevra.com. Telephone dial-in: US: (800) 579-2543; International: +1 (785) 424-1789. Conference ID: ZVRAQ325. Replay begins at ~5:30 p.m. ET on November 5, 2025.
Zevra Therapeutics (Nasdaq: ZVRA) announced on October 6, 2025 that it granted an aggregate of 38,000 stock options as inducement awards to two new employees under its 2023 Employment Inducement Award Plan.
Each award vests over four years with 25% vesting on the first anniversary of employment and the remainder vesting in three equal annual installments, subject to continued employment. The awards were approved by the Compensation Committee and granted as inducements in accordance with Nasdaq Rule 5635(c)(4). The Inducement Award Plan is reserved for individuals not previously employed by Zevra or returning after a bona fide non‑employment period.
Zevra Therapeutics (NASDAQ:ZVRA) has announced upcoming presentations of clinical data for its two key therapies at major scientific meetings. MIPLYFFA® (arimoclomol), the only treatment shown to halt Niemann-Pick disease type C progression at 12 months, will be featured at the INPDA Meeting in Argentina. The therapy has been administered to over 270 patients, representing the largest NPC clinical trial dataset.
Additionally, data on OLPRUVA® (sodium phenylbutyrate), a novel formulation for treating urea cycle disorders, will be presented. The presentations include an oral session at INPDA and multiple posters at the Child Neurology Society Annual Meeting, covering long-term efficacy, pediatric safety, and administration methods.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
